INDEX. Index. in this web service Cambridge University Press
|
|
- Jasmin May
- 5 years ago
- Views:
Transcription
1 INDEX A absorption problems, 63 4 acetylcholine and extrapyramidal side effects, memory pathways, action potentials, ion flow, aggression in dementia, citalopram for, link to orbital frontal cortex, 41 2 agitation, citalopram for, agomelatine, agoraphobia, alcoholism naltrexone for, reduced-risk drinking, allodynia, symptoms of, Alzheimer s disease (AD) and renal failure, contraindications, beta amyloid accumulation in brain, biomarkers for early detection, diagnosis of, L-methyl-folate efficacy, medications for smokers, order of symptoms, amantadine, for tardive dyskinesia, 75 6 amitriptyline, for fibromyalgia, amygdala and dopamine release, 277 8, and re-experiencing of PTSD symptoms, and suicidality, 81 2 anterior cingulate cortex, 232 and selective attention, antioxidant levels, increase in, antipsychotics bypassing absorption problems, 63 4 Del allele carriers response to, least likely to cause sedation, 67 8 therapeutic and side-effect profile, 47 8 weight gain and metabolic issues, 65 6, 77 8 anxiety and breathing difficulty, genes responsible for, apathy brain regions involved in, SSRI-induced indifference, apoptosis, 13 14, aripiprazole, 67 8, , asenapine, 63 4, 77 8 atomoxetine, 95 6, dose adjustment for liverdamaged patient, interaction with paroxetine, attention deficit hyperactivity disorder (ADHD) adult symptoms, identification of, and rapid discontinuation of clonidine, and substance use, atomoxetine and abuse potential, in this web service
2 312 attention deficit hyperactivity disorder (ADHD) (cont.) atomoxetine-paroxetine interaction, cortical maturation, children, lisdexamfetamine for adults, pulsatile stimulation leading to abuse, selective attention test, stimulant treatment for children, sustained attention, brain region involved in, axoaxonal connections, cell pairing, 9 10 axonal transport, 5 6 B basal forebrain, role in memory, benztropine, 75 6 beta adrenergic blockers, preemptive treatment for PTSD, beta-amyloid protein, accumulation in AD brain, biomarkers for early detection of AD, bipolar disorder brain area involved in symptoms, clinical course of, glutamate release, drugs reducing, medication during pregnancy, monoamine projections accounting for mania, mood stabilizer mechanism, rapid-cycling, medication for, recommended pharmacologic treatment, brain-derived neurotrophic factor (BDNF), reduced in chronic stress conditions, breast secretions, explanation for, breathing difficulty, parabrachial nucleus, buprenorphine, opioid addiction, bupropion and modafinil, depression treatment, contraindicated with phenelzine, buspirone, C caffeine consumption, night shift workers, cannabinoid CB1 receptor antagonism, catechol-o-methyltransferase (COMT) gene, 102 and depression, and susceptibility to worry and anxiety disorders, CBT (cognitive-behavioral therapy), for PTSD, chandelier neurons, axoaxonal connections, 9 10 chemical burn, afferent neuron response, cholinesterase inhibitors, Alzheimer s disease, chronic stress, effect on BDNF production and hippocampal volume, circadian rhythm agomelatine, role in modulating, effect of night shift work, phase-advanced, treatment for, role of melatonin, 31 2 classic synaptic neurotransmission, clomipramine overdose, effects of, 95 6 clonazepam, dose for panic disorder, in this web service
3 clonidine, effects of rapid discontinuation of, clozapine, side effects, codeine, effects of paroxetine on efficacy of, cognitive dysfunction depression-executive dysfunction, effect of milnacipran, in bipolar disorder, schizophrenia, cognitive flexibility, role of dorsolateral prefrontal cortex, cognitive performance in narcolepsy, cognitive restructuring therapy, cognitive-behavioral therapy (CBT), for PTSD, COMT gene, 102, , conventional antipsychotics, profile of, 47 8 corticotropin releasing hormone (CRH) gene expression, cross-titration, 69 70, 73 4 CYP450 1A2 enzyme inhibition by fluvoxamine, 97 8 smoking inducing, CYP450 2D6 enzyme inhibition, paroxetine, CYP450 enzymes, mirtazapine interaction, D D2 receptors, upregulation, 27 8 dementia citalopram for agitation and aggression, depression-executive dysfunction, depolarization, NMDA receptors, 35 6 depression-executive dysfunction, desvenlafaxine for VMS in depression, 87 8 diabetic peripheral neuropathy, donepezil, 75 6, 262, dopamine 2 receptor gene (DRD2), dopamine 2 receptor upregulation impetus for, 27 8 tardive dyskinesia, 45 6 dopamine deficiency causing daytime sleepiness, in prefrontal cortex, dopamine partial agonists (DPAs), switching to, 73 4 dopamine release due to natural highs, from amygdala to VTA, dorsolateral prefrontal cortex and sustained attention, role in cognitive flexibility, doxepin, effects of higher doses, drug hangover effect, drug tolerance, duloxetine, and chronic hepatitis, avoidance of, E electroconvulsive therapy (ECT), epigenetics, 33 4 escitalopram, eszopiclone for sleep cycle problems, plus sertraline for GAD, extrapyramidal side effects (EPS), adjunct medication, F fetus, neurogenesis stage, fibromyalgia, 183 4, milnacipran benefits, in this web service
4 314 fibromyalgia (cont.) pregabalin, molecular action, second-line monotherapy, fluoxetine, 103 4, G G protein coupling, 25 6 GABA-A receptors and sleep cycle disturbances, involved in panic attacks, gabapentin, galantamine, 261 2, generalized anxiety disorder (GAD), buspirone, mechanism of, effect on BDNF and hippocampal volume, eszopiclone plus sertraline, genetics COMT and MTHFR genes and depression, COMT Met genotype and anxiety, CRH gene and early-life stress, Del allele carriers, glutamate release drugs reducing, from pyramidal neurons, 91 2 glutamate, activating NMDA receptors, 35 6 glutamate-serotonin interactions, glycine, NMDA receptor activation, 35 6 H hallucinations, 25 6, 61 2 haloperidol, hepatitis, duloxetine contraindicated, hippocampus role in PTSD, volume decreased by chronic stress, histamine 1 (H1) receptor blockade and weight gain, 89 90, homeostatic (sleep) drive, unaffected by night shift work, homocysteine levels and AD, HPA axis functioning, changes caused by severe early-life stress, hyperalgesia, hypertension and rapid discontinuation of clonidine, tranylcypromine-tyramine reaction, 93 4 hypothalamus link to apathy, weight gain and insomnia, link to sleep problems, I ibuprofen and lithium toxicity, inefficacy for fibromyalgia, iloperidone for prevention of orthostatic hypotension, 55 6 weight and metabolic profiles, 77 8 indifference, SSRI-induced, infection, side effects of, insomnia and anxiety, treatment for, brain region associated with, trazodone for, ion channels, transmembrane, 23 4 ion flow during action potential, in this web service
5 K kinase phosphorylation of CREB, 25 6 L lamotrigine, , and quetiapine for bipolar disorder, reducing glutamate release, ligand-gated ion channels, 23 4 NMDA receptors, activation of, 35 6 lisdexamfetamine, adult ADHD, lithium, contraindicated in pregnancy, increasing antioxidant levels, toxic when combined with ibuprofen, liver damage atomoxetine dose adjustment, duloxetine contraindicated, L-methylfolate (MTHF) boosting efficacy of antidepressants, efficacy in Alzheimer s disease, lurasidone, 77 8 M mania symptoms, monoamine projections resulting in, marijuana abuse, rimonabant, medication absorption problems, 63 4 melatonin, 31 2, , memantine, properties useful in treating AD, memory brain regions involved in, re-experiencing of, menopause and depression, 87 8 meperidine, contraindicated with MAOIs, mesolimbic pathway, dopamine release, migraines in children, topiramate, milnacipran, mirtazapine CYP450 enzyme interaction, weight gain side effect, mitochondrial dysfunction, modafinil + bupropion, depression treatment, monoamine oxidase inhibitors (MAOIs) opioids contraindicated, reaction with tyramine in food, 93 4 monoamine projections and mania symptoms, monoamine synthesis, L-methylfolate, MTHFR gene, role in depression, mu-opioid receptors, naltrexone blocking, , 292 muscarinic 1 antagonism, EPS relief, N naltrexone for alcoholism, mechanism of action, narcolepsy, role of stimulants, natural highs, dopamine release, necrosis, nerve growth factor (NGF), 21 2 neurogenesis, fetal, neurons, signal transduction, 1 2 neuropathic pain, and chronic hepatitis, avoidance of duloxetine, in this web service
6 316 neuropathic pain (cont.) milnacipran for, neuroscience action potentials, nerve growth factor (NGF), 21 2 neurogenesis, fetal, neurotransmission, 19 20, 21 2 protein synthesis, site of, 3 4 receptor speed, 5 6 signal transduction, site of, 1 2 synapses, scaffolding process, neurotransmission, 19 20, 21 2, 27 8 agoraphobia, circadian rhythm, 31 2 dementia, pain relief, nicotine cravings, recovery from, night shift workers, caffeine consumption, nitric oxide synthetase (NOS) inhibition and sexual dysfunction, 85 6 N-methyl-d-aspartate (NMDA) memantine and treatment of AD, receptor activation, 35 6 nociceptive neuronal activity, nonsteroidal anti-inflammatory drugs (NSAIDs), lithium toxicity, nucleus accumbens, 41 2, 81 2, 133 4, , O obesity value of rimonabant, olanzapine, , 146 effects of higher doses, 51 2 effects of smoking on efficacy of, 61 2, hypnotic effect of, opiate addiction buprenorphine treatment, recovery potential, opioids contraindicated with MAOIs, paroxetine and codeine efficacy, orbital frontal cortex aggressive symptoms, 41 2 and mania symptoms, impulsivity regulation, 232 orthostatic hypotension, 55 6 P pain allodynia, symptoms of, chemical burn, neuron response, continued experience of, diabetic peripheral neuropathy, inconsistent effects of SSRIs, paliperidone, 63 4, 67 8 panic attacks/panic disorder, clonazepam dosage, GABA-A receptors involved in, neurotransmitters implicated in, parabrachial nucleus, respiration regulation, paroxetine and atomoxetine interaction, and decreased effectiveness of codeine, for PTSD, pharmacokinetics of, 85 6 periodic limb movement disorder (PLMD), perphenazine, 49 50, 67 8 phase-advanced circadian rhythms, treatment for, in this web service
7 phasic/pulsatile vs. tonic/sustained stimulation, polysomnograph test for PLMD/ PLMS, posttraumatic stress disorder (PTSD) and comorbid SUD, safety therapy, anxiolytic effects of sertraline, brain regions involved in, cognitive restructuring therapy, fear extinction therapy, first-line treatment, preemptive treatment for, stress diathesis hypothesis, prefrontal cortex and memory, atomoxetine inhibiting NET, decreased dopamine, overactivity, treatment for, 91 2 pyramidal cells, 7 8 pregabalin, 193 4, 197 8, pregnancy bipolar disorder medication, fetal neurogenesis, prolactin release, explanation for, propranolol preempting development of PTSD, protein synthesis, site of, 3 4 proteins, direction and speed of discarded, 5 6 psychosis brain region linked to aggression, 41 2 detecting negative symptoms, 37 8 pyramidal cells/neurons, 7 8 axoaxonal connections, 9 10 glutamate release, 91 2 Q quetiapine and lamotrigine for bipolar disorder, receptor blockade causing weight gain, relieving breast secretions, R rapid-cycling bipolar disorder, valproate, reduced-risk drinking, relapse, depression, reserpine, 75 6 respiration difficulties, anxiety, retrograde neurotransmission, 21 2 reward brain circuits, rimonabant, risperidone, 63 4, 65 6 cross-titration as switching method, target therapeutic dose for adolescent, 71 2 rivastigmine, 261 2, rough endoplasmic reticulum, protein synthesis, 3 4 S safety therapy, comorbid SUD and PTSD, scaffolding, synapses, schizophrenia and extrapyramidal side effects (EPS), cognitive functioning in, development of tardive dyskinesia, 45 6 early neurogenesis regulated by DISC-1 protein, 43 4 effects of higher doses of olanzapine, 51 2 hallucinogenic effect of smoking, 61 2 iloperidone for prevention of orthostatic hypotension, in this web service
8 318 schizophrenia (cont.) medication absorption problems, 63 4 medication least likely to cause sedation, 67 8 serotonin 2A antagonism, 53 4 target therapeutic dose for adolescent, 71 2 sedation, lowest risk medication, 67 8 selective attention, test of, selective serotonin reuptake inhibitors (SSRIs) benefits of adding to hypnotics, inconsistent effects on pain, indifference induced by, meperidine contraindicated with MAOIs, serotonin 1A receptors, effect of buspirone, serotonin 2A antagonism, 53 4, serotonin 2C antagonism and agomelatine binding, and weight gain, 57 8, 89 90, serotonin 5HT7 receptors, function of, serotonin antagonist/reuptake inhibitors (SARIs), 91 2 serotonin dopamine antagonists (SDAs), switching from, 73 4 serotonin transporter (SERT) gene, sertraline anxiolytic effects of, plus eszopiclone for GAD, sexual dysfunction due to NOS inhibition, 85 6 treatment combination for, signal transduction site, neurons, 1 2 sleep problems daytime sleepiness and dopamine deficiency, eszopiclone treatment, hypnotic effect of olanzapine, hypothalamus linked to, 133 4, narcolepsy, cognitive performance restored with stimulants, sertraline plus eszopiclone for GAD, sleep/wake switch, treatment for resetting, trazodone for inducing sleep, smoking cessation, pharmacologic therapy, recovery from nicotine addiction, reducing olanzapine efficacy, therapeutic value of rimonabant, social anxiety disorder, stimulants for ADHD in children, phasic/pulsatile delivery leading to abuse, restoring cognitive performance in narcolepsy, stress and changes in HPA axis functioning, and hippocampal volume decrease, stress diathesis hypothesis, PTSD, Stroop task, selective attention test, substance abuse and comorbid ADHD, preferred treatment order, substance abuse and comorbid PTSD, therapy for, in this web service
9 suicidality, role of amygdala, 81 2 suprachiasmatic nucleus (SCN), 31 2 treatment for resetting, sustained attention, brain region involved in, synapses, scaffolding process, T tardive dyskinesia, 45 6, 75 6 theophylline, inhibition by fluvoxamine, 97 8 titration schedules iloperidone, 55 6 varenicline, when adding lamotrigine to valproate, ziprasidone, topiramate, for migraine, dose range for children, tranylcypromine, tyramine reaction, 93 4 trazodone, 103 4, tyramine in food, reaction with MAOIs, 93 4 U unipolar depression antipsychotic drug response, Del allele carriers, brain-derived neurotrophic factor (BDNF), clomipramine overdose, effects of, 95 6 COMT and MTHFR genes, desvenlafaxine for VMS, 87 8 electroconvulsive therapy (ECT) for, fluoxetine for, fluvoxamine and theophylline, 97 8 L-methylfolate, value of, V mirtazapine, CYP450 enzyme interaction, relapse, symptom renewal, SARIs moderating glutamate release, 91 2 sexual dysfunction as medication side effect, 85 6, SSRIs, indifference induced by, suicidality, role of amygdala, 81 2 symptoms, cause of, 83 4 tranylcypromine, tyramine reaction, 93 4 weight gain, mirtazapine side effect, valproate, contraindicated in pregnancy, for rapid-cycling bipolar disorder, reduction of glutamate release, varenicline, smoking cessation, vasomotor symptoms (VMSs), desvenlafaxine, 87 8 venlafaxine, 95 6 ventral tegmental area (VTA), dopamine release from amygdala, ventromedial prefrontal cortex, link to mania symptoms, voltage-sensitive calcium channels (VSCCs) and excessive stimulation of glutamate release, and pain alleviation, voltage-sensitive sodium channels (VSSCs) drugs blocking, 96, pain transduction and conduction, in this web service
10 W weight gain and antipsychotics, 65 6, 77 8 and inefficient information processing in hypothalamus, due to antagonism of serotonin 2C receptors, 57 8 Z mirtazapine causing, quetiapine inducing receptor blockade, topiramate dosage for children, ziprasidone, 65 6, , in this web service
PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX
A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More information176 Stahl s Illustrated. in this web service Cambridge University Press
Stahl s Illustrated acamprosate, 104, 122 3, 148, 149 acceptance and commitment therapy (ACT), 135, 139, 147, 153 accidents, and risk of PTSD, 36 adherence, to medication by PTSD patients with traumatic
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationStudy Guide Unit 3 Psych 2022, Fall 2003
Psychological Disorders: General Study Guide Unit 3 Psych 2022, Fall 2003 1. What are psychological disorders? 2. What was the main treatment for some psychological disorders prior to the 1950 s? 3. What
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationFinal Exam PSYC2022. Fall (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication with cannabis.
Final Exam PSYC2022 Fall 1998 (2 points) Give 2 reasons why it is important for psychological disorders to be accurately diagnosed. (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationPsychopharmacology: A Comprehensive Review
Psychopharmacology: A Comprehensive Review 1) The association between a chemical compound and its biological activity, pioneered by Bovet and colleagues in the 1930s is known as a) Symbiosis b) Structure-activity
More informationSouth London and the Maudsley NHS Foundation Trust Medicines Formulary
South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationNEUROBIOLOGY ALCOHOLISM
NEUROBIOLOGY ALCOHOLISM THERE HAS BEEN A MAJOR THEORETICAL SHIFT IN MEDICATION DEVELOPMENT IN ALCOHOLISM Driven by animal models of intermittent ethanol administration followed by termination, then access
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationDeep brain stimulation (DBS), therapyresistant
Subject Index N-Acetyl aspartate, magnetic resonance spectroscopy studies in 104 α 2 -Adrenergic receptor, therapeutic targeting 13 Adrenocorticotropic hormone (ACTH) Agomelatine, mechanism of action 4,
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationWhite Paper. The Genes Analyzed by the Genecept Assay. May dynacare.ca
White Paper The Genes Analyzed by the Genecept Assay May 2017 888.988.1888 DynacareNext@dynacare.ca dynacare.ca GEN-WP003-v5-052017 INTRODUCTION Dynacare is pleased to present this summary of the genes
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationESSENTIAL PSYCHOPHARMACOLOGY, Neurobiology of Schizophrenia Carl Salzman MD Montreal
ESSENTIAL PSYCHOPHARMACOLOGY, 2011 Neurobiology of Schizophrenia Carl Salzman MD Montreal EVOLVING CONCEPTS OF SCHIZOPHRENIA Psychotic illness with delusions, hallucinations, thought disorder and deterioration;
More informationObjectives. Mental Health Info MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES 11/12/2018
MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES Holly Altenberger, PharmD, RPh Director of Pharmacy O Connell Pharmacy holly@oconnellpharmacy.com Objectives At the conclusion of the
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationIn Memory of the American Tragedy
Evolving Pharmacologic Strategies in the Treatment of PTSD John J. Miller, M.D. Medical Director Brain Health Exeter, NH In Memory of the American Tragedy September 11, 2001 jjm@brain-health.co 1 Overview
More informationSession ID: 1001 June 14, 2012
It s Not Just Serotonin: Neurosignaling in Mental Illness Barbara J. Limandri, DNSc, APRN, BC Professor of Nursing Linfield College Learning Outcomes Distinguish between metabotropic and ionotropic neuroreceptors
More informationIt s Not Just Serotonin: Neurosignaling in Mental Illness
It s Not Just Serotonin: Neurosignaling in Mental Illness Barbara J. Limandri, DNSc, APRN, BC Professor of Nursing Linfield College Learning Outcomes Distinguish between metabotropic and ionotropic neuroreceptors
More informationPHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS
PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS Yogesh Dwivedi, Ph.D. Assistant Professor of Psychiatry and Pharmacology Psychiatric Institute Department of Psychiatry
More information3. Atypical antidepressants
3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationAnswer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.
CLINICAL THERAPEUTICS 7: PSYCHIATRY PHA-MHBY Time allowed: 2 hours UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 Part ONE Answer ALL questions. For each question, there
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationTreating Depression in Adults
Treating Depression in Adults By Deborah Christensen, Ph.D., M.S.C.P. Depressive Disorders represent a broad and heterogeneous group of commonly diagnosed psychological disorders. The DSM adequately describes
More informationAnti-Depressant Medications
Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change
More informationMental illness A Broad Overview. Dr H Pathmanandam March 2017
Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate
More informationDisclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015
49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University
More informationWhite Paper. The Science Behind the Genecept Assay. January, 2016
White Paper The Science Behind the Genecept Assay January, 2016 Genomind, Inc. 2200 Renaissance Blvd Suite 100 King of Prussia, PA 19406 877.895.8658 www.genomind.com GEN WP003 v3 01182016 INTRODUCTION
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationSafe transfer of prescribing guidance
Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed
More informationNSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.
Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationIndex. baclofen 73 basal forebrain nuclei 174
Index acetazolamide 33 acetylcholine esterase inhibitor 174 actigraphy 14 activity meter 226 acute insomnia 4 α1 adrenergic activity 88 α 1 containing receptor 211 adenosine 108 advanced sleep phase syndrome
More informationExpected Outcomes. Assumptions. Borderline Personality Disorder: Pharmacologic Intervention
Borderline Personality Disorder: Pharmacologic Intervention Barbara J. Limandri, DNSc, APRN, BC Associate Professor Linfield College School of Nursing PMHNP Portland Dialectical Behavior Therapy Program
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationNeuro Basics SLO Practice (online) Page 1 of 5
Neuro Basics SLO Practice (online) Page 1 of 5 1) Biogenic amines include ACh, NE, EPI and? a) Melatonin b) Dopamine c) Serotonin d) Histamine e) All of the neurotransmitters listed are biogenic amines.
More informationIndex. Index. More information
acamprosate, alcohol dependence, 223 225, 227 228, 252 acetylcholine, role in Alzheimer s disease, 263 aerobic exercise, panic disorder, 81 agitation, schizophrenia sedation strategies, 21 agomelatine,
More informationPsychiatric Pharmacotherapy { Objectives. Overview 4/5/2016
Psychiatric Pharmacotherapy { Elizabeth Lake, PharmD PGY1 Pharmacy Practice Resident G.V. Sonny Montgomery VA Medical Center Objectives The purpose of this activity is to enable the nurse practitioner
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationChapter Sixteen. Psychological Disorders
Chapter Sixteen Psychological Disorders Prevalence of Psychological Disorders? Approximately 25% of the Adult Population here in the U.S. of A. Higher percentages in areas / countries with high poverty
More informationThe future of pharmacological treatment.
The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationNew Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
More informationPrescriber s Guide. Stahl s Essential Psychopharmacology
Stahl s Essential Psychopharmacology Prescriber s Guide FIFTH EDITION With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationPsychotropic Drugs 0, 4-
0, 4- } -v Psychotropic Drugs NORMAN L. KELTNER, Ed D, RN Associate Professor, Graduate Program, University of Alabama School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama DAVID
More information48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014
48 th Annual Meeting Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Published in 2013 Most published treatment guidelines
More informationRuby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018
Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationThe Neurobiology of Mood Disorders
The Neurobiology of Mood Disorders J. John Mann, MD Professor of Psychiatry and Radiology Columbia University Chief, Department of Neuroscience, New York State Psychiatric Institute Mood Disorders are
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationMedications, By Class, in TBI
Medications, By Class, in TBI Generic/Brand Name Drawback Advantage Mood Stabilizers (anti-seizure medications) Carbamazepine (Carbatrol ) (Equetro ) (Tegretol ) Gabapentin (Neurontin ) Lamotrigine (Lamictal
More informationΝευροφυσιολογία και Αισθήσεις
Biomedical Imaging & Applied Optics University of Cyprus Νευροφυσιολογία και Αισθήσεις Διάλεξη 19 Ψυχασθένειες (Mental Illness) Introduction Neurology Branch of medicine concerned with the diagnosis and
More informationAffective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018
Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationJoint Formulary for Psychotropic Medication.
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories
More informationIndex. E Elderly and dementia, 2 Epilepsy, 59 Escitalopram, 51, 87 Estazolam, 101 Extrapyramidal symptoms (EPS), 18
A Abilify, 143 Absolute neutrophil count (ANC), 29 Acetylcholine (Ach), 14, 15 ACTivities of daily living and cognition (ACTION) study, 167 AD Anti-inflammatory Prevention Trial (ADAPT) study, 156 Adverse
More informationUnderstanding the Brain: What Drugs Can Tell Us
LIVE INTERACTIVE LEARNING @ YOUR DESKTOP Understanding the Brain: What Drugs Can Tell Us Presented by: Dr. Rochelle D. Schwartz-Bloom March 24, 2011 Understanding the Brain: What Drugs Can Tell Us Rochelle
More informationConflict of Interest Slide
The Trials, Tribulations, and Treatment of PTSD Douglas L Boggs, PharmD., MS, BCPP Douglas.Boggs@yale.edu VISN 1 Academic Detailer Clinical Pharmacy Specialist-Mental Health VA Connecticut Healthcare System
More informationTreating sleep disorders
Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationBRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.
BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationAn update on the pharmacology of anxiolytics for the anxiety, obsessive compulsive and post-traumatic stress disorders
An update on the pharmacology of anxiolytics for the anxiety, obsessive compulsive and post-traumatic stress disorders Kim Outhoff, MBChB, MFPM, Senior Lecturer, Department of Pharmacology, University
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationThis document has been produced in collaboration with the Lancashire Commissioning Support Unit
Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationPsychopathology: Biological Basis of Behavioral Disorders
1 6 Psychopathology: Biological Basis of Behavioral Disorders 16 Psychopathology: Biological Basis of Behavioral Disorders The Toll of Psychiatric Disorders Is Huge Schizophrenia is the major neurobiological
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationDepression Pharmacology. PHPP 517 (IT-III) Fall 2011
Depression Pharmacology PHPP 517 (IT-III) Fall 2011 Depression Symptoms of Depression Emotional symptoms Physical symptoms Cognitive symptoms Psychomotor symptoms Depression Pharmacology Loss of brain
More information6B / Boswell, Grant and Slutske Day 2 August 14, 2008
Pharmacological Treatment of Pathological Gambling Jon E. Grant, JD, MD, MPH Associate Professor University of Minnesota School of Medicine Minneapolis, MN Disclosure Information I have the following financial
More information